Biotech entity

Voyager Technologies, Inc.

Company VYGR

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Miplyffa, the most common co-covered peer. The tracked stories average 2 original sources each. Voyager Technologies, Inc. appears in 1 tracked Biotech story from March 8, 2026.

Last mentioned: Mar 8, 2026

RSS updates
Share

Entity pulse

Recent coverage · Voyager Technologies, Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Voyager Technologies, Inc.

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Miplyffa, the most common co-covered peer. The tracked stories average 2 original sources each. Voyager Technologies, Inc. appears in 1 tracked Biotech story from March 8, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Voyager Technologies, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Earnings

    Both companies report full-year 2025 results and 2026 guidance.

  2. Olpruva Scaling

    Zevra reports steady growth in urea cycle disorder market share.

  3. Novartis Expansion

    Voyager expands its capsid discovery collaboration with Novartis.

  4. Miplyffa Approval

    Zevra receives FDA approval for arimoclomol in NPC treatment.

Stories mentioning Voyager Technologies, Inc. 1

Pharma Neutral

Voyager and Zevra Set for Q4 Earnings Amid Commercial and Pipeline Shifts

Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.

2 sources

Voyager Technologies, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.